Demonstrates Potential for ET-02 to be Significantly More Effective Than Existing Treatments for Hair Loss

Palvella Therapeutics Awarded Up to $2.6 million Grant

Avive Solutions Raises $56.5M in Growth Funding To Build Connected AED Network and Transform Cardiac Arrest Emergency Response in...

SOUTHLAKE, Texas, Jan. 8, 2024 /PRNewswire/ -- Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations...

Liquid biopsy startup AOA Dx has collected $17 million to support the development of its diagnostic test for ovarian cancer...

Transactions Advance Amwell’s Strategy to Enable Health Systems’ and Health Plans’ Telehealth Programs with Ongoing Organic and Inorganic...

Titled "A Game-Changer: Conversa Health’s Automated Virtual Care Platform was Built to Support the Hybrid-Care Model of the Future" the...

Eirion Therapeutics, Inc. Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd.

Conversa Health, a leading virtual care and triage platform, has expanded its Series B financing to $20 million

Women’s Health USA, QED Investors, LabCorp, Fool Ventures and Gore Range Capital participated in this round.

WORCESTER, Mass.--(BUSINESS WIRE)-- Or-Genix Therapeutics, Inc., a development-stage specialty woman’s health and dermatology company,...

Castle Biosciences, Inc. announced today the pricing of its IPO of 4,000,000 shares of its common stock at a price of $16/share

Cristina Griffin Joins Or-Genix Therapeutics as Chief Business Officer

Castle Biosciences filed on Wednesday with the SEC to raise up to $58 million in an initial public offering.